These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
112 related items for PubMed ID: 3244662
1. Formulation of vaccine adjuvant muramyldipeptides (MDP). 1. Characterization of amorphous and crystalline forms of a muramyldipeptide analogue. Chan TW, Becker A. Pharm Res; 1988 Aug; 5(8):523-7. PubMed ID: 3244662 [Abstract] [Full Text] [Related]
2. Formulation of vaccine adjuvant muramyldipeptides (MDP). 2. The thermal reactivity and pH of maximum stability of MDP compounds in aqueous solution. Powell MF, Foster LC, Becker AR, Lee W. Pharm Res; 1988 Aug; 5(8):528-32. PubMed ID: 3244663 [Abstract] [Full Text] [Related]
4. Formulation of vaccine adjuvant muramyldipeptides. 3. Processing optimization, characterization, and bioactivity of an emulsion vehicle. Lidgate DM, Fu RC, Byars NE, Foster LC, Fleitman JS. Pharm Res; 1989 Sep; 6(9):748-52. PubMed ID: 2813271 [Abstract] [Full Text] [Related]
5. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats. Kohashi O, Kohashi Y, Shigematsu N, Ozawa A, Kotani S. Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128 [Abstract] [Full Text] [Related]
6. Chemical modification of the C-6 substituent in the carbohydrate moiety of N-acetylmuramoyl-L-alanyl-D-isoglutamine (MDP), and the immunoadjuvant activity. Okumura H, Tokushima Y, Saiki I, Azuma I, Kiso M, Hasegawa A. Carbohydr Res; 1983 Oct 14; 122(1):87-98. PubMed ID: 6652634 [Abstract] [Full Text] [Related]
7. The measurement of the β/α anomer composition within amorphous lactose prepared by spray and freeze drying using a simple (1)H-NMR method. Jawad R, Elleman C, Vermeer L, Drake AF, Woodhead B, Martin GP, Royall PG. Pharm Res; 2012 Feb 14; 29(2):511-24. PubMed ID: 21901569 [Abstract] [Full Text] [Related]
10. Studies on the stability of muroctasin and degradation products built under extreme conditions. Moroi R, Yamazaki K, Hirota T, Watanabe S, Oki M, Toriyama M, Ichinohe A, Kataoka K. Arzneimittelforschung; 1988 Jul 14; 38(7A):959-68. PubMed ID: 3190803 [Abstract] [Full Text] [Related]
13. [Immunochemistry of tubercle bacilli, with special reference to adjuvant activity (author's transl)]. Azuma I. Kekkaku; 1981 Dec 14; 56(12):595-607. PubMed ID: 7035731 [No Abstract] [Full Text] [Related]
16. Chemical synthesis and adjuvant activity of N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) analogs 1, 2. Kamisango K, Saiki I, Tanio Y, Kobayashi S, Fukuda T, Sekikawa I, Azuma I, Yamamura Y. Chem Pharm Bull (Tokyo); 1981 Jun 14; 29(6):1644-54. PubMed ID: 7296716 [No Abstract] [Full Text] [Related]
17. Immunological activities of multiprenylacetyl derivatives of muramyldipeptides. Azuma I, Saiki I, Iida J, Fukuda T, Kobayashi S. Vaccine; 1988 Aug 14; 6(4):339-42. PubMed ID: 2847438 [Abstract] [Full Text] [Related]